Laminates containing an active substance transdermal system
View Patent ↗The transdermal system includes a sex hormone-containing adhesive matrix, which contains inclusions of a sex hormone in a hydrophilic non-crosslinked polymer in dissolved or dispersed form. The inclusions have a concentration of 20 to 90 percent by weight of the sex hormone, which is more than 50 percent by weight amorphous. The hydrophilic non-crosslinked polymer can be polyvinylpyrrolidone, methylcellulose, ethylcellulose or hydroxyethylcellulose. The adhesive matrix can be a polyisobutylene, ethylene-vinyl-acetate copolymer or a polystyrene-butadiene block copolymer.
1. A transdermal system comprising a substrate and a sex hormone-containing adhesive matrix, wherein said sex hormone-containing adhesive matrix contains solid inclusions in dissolved form or dispersed form, said solid inclusions consist of a hydrophilic non-crosslinked polymer and a sex hormone, said solid inclusions have a concentration of said sex hormone of 20 to 90 percent by weight and said sex hormone is more than 95 percent by weight amorphous.
2. The transdermal system according to claim 1 , wherein said solid inclusions are present in the adhesive matrix in said dissolved form.
3. The transdermal system according to claim 1 , wherein said solid inclusions are present in the adhesive matrix in said dispersed form.
4. The transdermal system according to claim 1 , wherein said hydrophilic non-crosslinked polymer is polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxyethylcellulose, or mixtures thereof.
5. The transdermal system according to claim 1 , wherein said adhesive matrix comprises at least one material selected from the group consisting of polyisobutylenes, ethylene-vinyl-acetate copolymers and polystyrene-butadiene block copolymers.
6. The transdermal system according to 1 , wherein said sex hormone in said solid inclusions is 100 percent by weight amorphous, as determined by X-ray powder diffraction measurements.
7. The transdermal system according to one of claims 1 and 6 , wherein said solid inclusions contain more than 50 percent by weight of said sex hormone, but not more than 90 percent by weight of said sex hormone.
8. A transdermal system comprising a substrate and a sex hormone-containing adhesive matrix, wherein said sex hormone-containing adhesive matrix contains dispersed solid inclusions and said solid inclusions consist of a hydrophilic non-crosslinked polymer and a sex hormone, said solid inclusions have a concentration of said sex hormone of 20 to 90 percent by weight and said sex hormone is more than 95 percent by weight amorphous.
9. The transdermal system according to claim 8 , wherein said hydrophilic non-crosslinked polymer is polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxyethylcellulose, or mixtures thereof.
10. The transdermal system according to claim 8 , wherein said adhesive matrix comprises at least one polymeric adhesive material selected from the group consisting of polyisobutylenes, ethylene-vinyl-acetate copolymers and polystyrene-butadiene block copolymers.
11. A transdermal system comprising a substrate and a sex hormone-containing adhesive matrix, wherein said sex hormone-containing adhesive matrix is formed by dissolving solid inclusions in a polymeric adhesive, said solid inclusions consist of a hydrophilic non-crosslinked polymer and a sex hormone, said solid inclusions have a concentration of said sex hormone of 20 to 90 percent by weight and said sex hormone Is more than 95 percent by weight amorphous.
12. The transdermal system according to claim 11 , wherein said hydrophilic non-crosslinked polymer is polyvinylpyrrolidone, methylcellulose, ethylcellulose, hydroxyethylcellulose, or mixtures thereof.
13. The transdermal system according to claim 11 , wherein said polymeric adhesive is selected from the group consisting of polyisobutylenes, ethylene-vinyl-acetate copolymers and polystyrene-butadiene block copolymers.
14. The transdermal system according to one of claims 1 , 8 and 11 , containing no absorption accelerators or enhancers for increasing a flux of said sex hormone through skin.
15. The transdermal system according to claim 8 or 11 , wherein said sex hormone in said solid inclusions is 100 percent by weight amorphous, as determined by X-ray powder diffraction measurements.